Articles

O.19 Overall survival improvement in metastatic clear-cell renal cell carcinoma patients from 2000 to 2020

BJMO - 2021, issue 3, march 2021

Sofie Demasure , Isabel Spriet , Philip R. Debruyne , Annouschka Laenen , Wim Wynendaele , Marcella Baldewijns , Herlinde Dumez , Paul M. Clement , Hans Wildiers , Patrick Schöffski , Eduard Rousse , Lisa Kinget , Maarten Albersen , Benoit Beuselinck

Introduction: Only a limited number of recent phase III studies with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), mTOR-inhibitors or immune checkpoint inhibitors (ICI) in metastatic clear-cell renal cell carcinoma (m-ccRCC) could show an overall survival (OS) benefit compared to standard of care. We aimed to study the evolution of OS of m-ccRCC patients during the last 20-years period (2000–2020).

Read more
X